ImmuCell Corporation (ICCC) Announces Earnings Results
ImmuCell Corporation (NASDAQ:ICCC) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.07) EPS for the quarter, Bloomberg Earnings reports. The company had revenue of $2.01 million during the quarter. ImmuCell Corporation had a return on equity of 0.28% and a net margin of 0.60%.
ImmuCell Corporation (NASDAQ:ICCC) opened at $8.99 on Wednesday. ImmuCell Corporation has a 12 month low of $4.76 and a 12 month high of $9.24. The firm has a market cap of $42.44, a price-to-earnings ratio of 840.06 and a beta of 1.16. The company has a quick ratio of 1.28, a current ratio of 1.89 and a debt-to-equity ratio of 0.18.
Separately, ValuEngine raised shares of ImmuCell Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th.
ImmuCell Corporation Company Profile
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.
Receive News & Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related companies with MarketBeat.com's FREE daily email newsletter.